261 related articles for article (PubMed ID: 31414566)
21. Patterns of Care and Outcomes of Adjuvant Chemoradiation for Node-Positive Pancreatic Adenocarcinoma.
Malakhov N; Lee A; Albert A; Lederman A; Byun J; Safdieh J; Schreiber D
J Gastrointest Cancer; 2020 Jun; 51(2):506-514. PubMed ID: 31236851
[TBL] [Abstract][Full Text] [Related]
22. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
[TBL] [Abstract][Full Text] [Related]
23. Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma: Evidence from a nationwide clinical oncology database and review of the literature.
Datta J; Ecker BL; Neuwirth MG; Geha RC; Fraker DL; Roses RE; Karakousis GC
Surg Oncol; 2017 Jun; 26(2):117-124. PubMed ID: 28577717
[TBL] [Abstract][Full Text] [Related]
24. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
[TBL] [Abstract][Full Text] [Related]
25. Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma.
Topal H; Aerts R; Laenen A; Collignon A; Jaekers J; Geers J; Topal B
JAMA Netw Open; 2022 Dec; 5(12):e2248147. PubMed ID: 36547979
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
27. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.
Amin S; Baine M; Meza J; Alam M; Lin C
Radiat Oncol; 2020 Jun; 15(1):139. PubMed ID: 32493354
[TBL] [Abstract][Full Text] [Related]
28. A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
Ozer M; Goksu SY; Sanford NN; Porembka M; Khurshid H; Ahn C; Maxwell MC; Beg MS; Kazmi SM
JAMA Netw Open; 2022 Feb; 5(2):e2146912. PubMed ID: 35171262
[TBL] [Abstract][Full Text] [Related]
29. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
30. Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base.
Amini A; Waxweiler TV; Brower JV; Jones BL; McDermott JD; Raben D; Ghosh D; Bowles DW; Karam SD
JAMA Otolaryngol Head Neck Surg; 2016 Nov; 142(11):1100-1110. PubMed ID: 27541166
[TBL] [Abstract][Full Text] [Related]
31. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
[TBL] [Abstract][Full Text] [Related]
32. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
34. Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis.
Kamarajah SK; Bednar F; Cho CS; Nathan H
J Gastrointest Surg; 2021 Jul; 25(7):1805-1814. PubMed ID: 33230687
[TBL] [Abstract][Full Text] [Related]
35. Survival after Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit?
Arrington AK; Hsu CH; Schaefer KL; O'Grady CL; Khreiss M; Riall TS
J Am Coll Surg; 2021 Jul; 233(1):100-109. PubMed ID: 33781861
[TBL] [Abstract][Full Text] [Related]
36. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
37. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
[TBL] [Abstract][Full Text] [Related]
38. Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation.
Anderson JD; Wan W; Kaplan BJ; Myers J; Fields EC
J Gastrointest Oncol; 2016 Dec; 7(6):1004-1010. PubMed ID: 28078125
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of additional therapy for residual pancreatic cancer.
Yamada S; Sonohara F; Tashiro M; Murotani K; Takami H; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujii T; Kodera Y
Surg Today; 2020 May; 50(5):440-448. PubMed ID: 31650262
[TBL] [Abstract][Full Text] [Related]
40. Survival benefit of adjuvant chemotherapy following neoadjuvant therapy and oesophagectomy in oesophageal adenocarcinoma.
Kamarajah SK; Markar SR; Phillips AW; Kunene V; Fackrell D; Salti GI; Dahdaleh FS; Griffiths EA
Eur J Surg Oncol; 2022 Sep; 48(9):1980-1987. PubMed ID: 35718676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
